UY32235A - PHARMACEUTICAL SYNERGIC COMBINATION UNDERSTANDING AN ANTIGONIST OF THE STROGEN RECEIVER AND A PROGESTINE - Google Patents

PHARMACEUTICAL SYNERGIC COMBINATION UNDERSTANDING AN ANTIGONIST OF THE STROGEN RECEIVER AND A PROGESTINE

Info

Publication number
UY32235A
UY32235A UY0001032235A UY32235A UY32235A UY 32235 A UY32235 A UY 32235A UY 0001032235 A UY0001032235 A UY 0001032235A UY 32235 A UY32235 A UY 32235A UY 32235 A UY32235 A UY 32235A
Authority
UY
Uruguay
Prior art keywords
antigonist
progestine
strogen
pharmaceutical
receiver
Prior art date
Application number
UY0001032235A
Other languages
Spanish (es)
Inventor
Dr Tim Wintermantel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32235A publication Critical patent/UY32235A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Coadministración de un antagonista del receptor de estrógeno y una progestina para tratar enfermedades ginecológicas que son el resultado del crecimiento anormal del tejido del útero, tales como la endometriosis o los fibroides uterinos.Co-administration of an estrogen receptor antagonist and a progestin to treat gynecological diseases that are the result of abnormal growth of uterine tissue, such as endometriosis or uterine fibroids.

UY0001032235A 2008-11-11 2009-11-10 PHARMACEUTICAL SYNERGIC COMBINATION UNDERSTANDING AN ANTIGONIST OF THE STROGEN RECEIVER AND A PROGESTINE UY32235A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008057230A DE102008057230A1 (en) 2008-11-11 2008-11-11 Synergistic pharmaceutical combination with an estrogen receptor antagonist and a progestin

Publications (1)

Publication Number Publication Date
UY32235A true UY32235A (en) 2010-06-30

Family

ID=41606625

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032235A UY32235A (en) 2008-11-11 2009-11-10 PHARMACEUTICAL SYNERGIC COMBINATION UNDERSTANDING AN ANTIGONIST OF THE STROGEN RECEIVER AND A PROGESTINE

Country Status (6)

Country Link
AR (1) AR074297A1 (en)
DE (1) DE102008057230A1 (en)
PA (1) PA8847901A1 (en)
TW (1) TW201022251A (en)
UY (1) UY32235A (en)
WO (1) WO2010054758A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120238533A1 (en) * 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
US20130231292A1 (en) * 2012-03-02 2013-09-05 Wei Zhou Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells
US10112962B2 (en) * 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
CN104370796B (en) * 2014-11-21 2016-09-14 扬子江药业集团有限公司 A kind of preparation method of bazedoxifene acetate polymorph b
KR20180059427A (en) * 2015-07-14 2018-06-04 노벨파마 컴퍼니 리미티드 Estrogen receptor beta partial agonist having an estrogen receptor alpha inhibitory action and a therapeutic agent for gynecological diseases using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19635525A1 (en) 1996-08-20 1998-02-26 Schering Ag New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives
ID24568A (en) * 1997-11-06 2000-07-27 American Home Prod ORAL CONTRACEPTION THAT CONTAINS ANTI-ESTROGEN PLUS PROGESTIN
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
WO2001009115A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
DE10013782A1 (en) 2000-03-15 2001-10-18 Schering Ag 4-fluoroalkyl-2H-benzopyrans with antiestrogenic activity, process for their preparation, pharmaceutical preparations containing them and their use in the manufacture of medicaments
DE10159217A1 (en) 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
WO2003063859A1 (en) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
NZ537138A (en) 2002-07-22 2007-11-30 Lilly Co Eli Selective estrogen receptor modulators containing a phenylsulfonyl group
US20080021003A1 (en) * 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen

Also Published As

Publication number Publication date
AR074297A1 (en) 2011-01-05
TW201022251A (en) 2010-06-16
PA8847901A1 (en) 2010-06-28
DE102008057230A1 (en) 2010-05-12
WO2010054758A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
CR20110455A (en) DERIVATIVES OF INDOL AS AN ANTHOGONIST OF THE CRTH2 RECEIVER
UY32819A (en) PHARMACEUTICAL COMPOSITIONS OF OPTALMIC USE OF ANTAGONISTS OF DP2 RECEIVER
GT201500233A (en) BENZOTIOPHEN DERIVATIVES AND COMPOSITIONS OF THE SAME AS SELECTIVE DEGRADANTS OF THE ESTROGEN RECEIVERS
CO6771417A2 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
GT201200147A (en) MDPI2 ESPIRO-OXINDOL ANTAGONISTS
CR20150296A (en) NEWS DERIVED FROM BENCIMIDAZOL AS ANTAGONISTS OF EP4
GT201600056A (en) DERIVATIVES OF QUINOLIZINE SUBSTITUTED USEFUL AS INHIBITORS OF HIV INTEGRASA
GT201300122A (en) ANTIGONISTS OF THE RECEIVER OF THE CGRP OF PIPERIDINONA CARBOXAMIDA AZAINDANO
NI201500004A (en) METHODS AND COMPOSITIONS TO DETERMINE RESISTANCE TO ANDROGEN RECEPTOR THERAPY.
CO6480918A2 (en) POLYCHYCLIC ANTAGONISTS OF LISOPHOSPHATIDIC ACID RECEPTORS.
UY32926A (en) COMPOUNDS AS ANTAGONISTS OF LISOPHOSPHATIDIC ACID RECEPTORS
UY30829A1 (en) AGONIST AND ANTAGONIST COMPOUNDS OF THE SPHINPHOSINE-1-PHOSPHATE RECEPTOR
CO6680708A2 (en) Modular estrogen compound and compositions comprising the same
CO6640327A2 (en) Pyrazole compounds as sigma receptor inhibitors
SV2010003687A (en) HYDROXIMETHYL PIRROLIDINS AS AGONISTS OF THE BETA 3 ADRENERGIC RECEIVER
AU2013235499A8 (en) Estrogen receptor modulators and uses thereof
HN2012000137A (en) DERIVATIVES OF 17 - HIDROXI - 17 - PENTAFLUOROETIL - ESTRA - 4, 9 (10) - DIEN - 11 - ARILO, PROCEDURES FOR THE PREPARATION AND USE FOR THE TREATMENT OF DISEASES
DOP2013000043A (en) COMPOSITIONS AND METHODS TO INHIBIT THE UNION OF MOTHER CELLS AND PROGENITATING CELLS TO LINFOID FABRIC AND TO REGENERATE GERMINAL CENTERS IN LYMPHATIC FABRICS
UY32235A (en) PHARMACEUTICAL SYNERGIC COMBINATION UNDERSTANDING AN ANTIGONIST OF THE STROGEN RECEIVER AND A PROGESTINE
CU20120175A7 (en) COMPOUNDS DERIVED FROM 6,7-DIHIDRO-5H-BENZO [7] ANNULARS
CO6420342A2 (en) PIRAZOL DERIVATIVES USED AS AN RECRUITOR OF THE CCR4 RECEIVER
BR112015030387A2 (en) pyrazole compounds as fshr modulators and uses thereof
GT201300241A (en) ANTIHIPERTENSIVE PHARMACEUTICAL COMPOSITION
UY35906A (en) NEWS DERIVED FROM BENCIMIDAZOL AS LIGANDOS OF EP4
CL2016002240A1 (en) Piperidine derivatives as orexin receptor antagonist

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127